Coherus BioSciences Inc
NASDAQ:CHRS

Watchlist Manager
Coherus BioSciences Inc Logo
Coherus BioSciences Inc
NASDAQ:CHRS
Watchlist
Price: 0.9786 USD 6.1% Market Closed
Market Cap: 113.4m USD

Operating Margin
Coherus BioSciences Inc

-52.8%
Current
-78%
Average
-5.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-52.8%
=
Operating Profit
-104.3m
/
Revenue
197.5m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Coherus BioSciences Inc
NASDAQ:CHRS
113.4m USD
-53%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
336.6B USD
30%
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
325.9B USD
-2 834%
US
Amgen Inc
NASDAQ:AMGN
165.8B USD
25%
US
Gilead Sciences Inc
NASDAQ:GILD
141.4B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
122.3B USD
38%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
128.6B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
61.9B USD
29%
US
Seagen Inc
F:SGT
39.3B EUR
-33%

Coherus BioSciences Inc
Glance View

Market Cap
113.4m USD
Industry
Biotechnology

Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. The company is headquartered in Redwood City, California and currently employs 332 full-time employees. The company went IPO on 2014-11-06. The firm is focused on the research, development and commercialization of immunotherapies to treat cancer. The company operates in the business of developing and commercializing the human pharmaceutical products segment. The Company’s product pipeline comprises three product candidates, toripalimab, an anti-PD-1 antibody being developed in collaboration with Junshi Biosciences Co., Ltd., CIMERLI, a Lucentis biosimilar candidate in-licensed for commercial rights in the United States and Canada from Bioeq, and a bevacizumab (Avastin) biosimilar in-licensed for commercial rights in the United States from Innovent Biologics (Suzhou) Co., Ltd. The company is also developing an internal immuno-oncology pipeline in preclinical and translational science, bioinformatics, analytical characterization, process science engineering, and clinical-regulatory development and commercialization.

CHRS Intrinsic Value
4.0907 USD
Undervaluation 76%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-52.8%
=
Operating Profit
-104.3m
/
Revenue
197.5m
What is the Operating Margin of Coherus BioSciences Inc?

Based on Coherus BioSciences Inc's most recent financial statements, the company has Operating Margin of -52.8%.

Back to Top